Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> TRP Channel>>SAR7334

SAR7334

Catalog No.GC33424 Copy One-Click Copy Product Info

SAR7334 is a highly potent and specific TRPC6 channel inhibitor (IC₅₀=7.9nM). SAR7334 also inhibits TRPC3- and TRPC7-mediated Ca²⁺ influx into cells.

Products are for research use only. Not for human use. We do not sell to patients.

SAR7334 Chemical Structure

Cas No.: 1333210-07-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$123.00
In stock
1mg
$64.00
In stock
5mg
$112.00
In stock
10mg
$179.00
In stock
50mg
$333.00
In stock
100mg
$416.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.



Description of SAR7334

SAR7334 is a highly potent and specific TRPC6 channel inhibitor (IC₅₀=7.9nM). SAR7334 also inhibits TRPC3- and TRPC7-mediated Ca²⁺ influx into cells[1-2]. SAR7334 can be used in research related to fibrotic diseases such as focal segmental glomerulosclerosis, skeletal muscle dysfunction, as well as pulmonary arterial hypertension and pulmonary edema[3-4].

In vitro, hippocampal neurons isolated from young, middle-aged, and aged mice were treated with SAR7334 (0.1μM or 1μM) for 15 minutes. SAR7334 dose-dependently reduced the resting intracellular calcium ([Ca²⁺]ᵣ) and sodium ([Na⁺]ᵣ) concentrations in neurons, with a more pronounced reduction observed in middle-aged and aged neurons compared to young ones[5]. MPC5 podocytes were pretreated with SAR7334 (1μM) for 30 minutes, followed by stimulation with AngII (1μM) for 24 hours. SAR7334 significantly inhibited the expression of TRPC6, AT1R, and Caspase-3 proteins, increased the expression of the podocyte structural proteins Nephrin and Podocin, and reduced intracellular Ca²⁺ fluorescence intensity and cell apoptosis[6].

In vivo, spontaneously hypertensive rats (SHR) were treated with SAR7334 (oral administration; 10mg/kg) for two days. Compared to the vehicle-treated control group, the SAR7334-treated group showed no significant change in mean arterial pressure (MAP)[7]. In establishing a chemotherapy-induced peripheral neuropathy (CIPN) mouse model via cisplatin intervention, SAR7334 (10mg/kg; i.p.) was administered beginning one day before the second cycle of cisplatin treatment and continued for 7 days. SAR7334 significantly alleviated cisplatin-induced CIPN symptoms, including improving the paw withdrawal threshold in mechanical allodynia tests, shortening the response time to an adhesive stimulus, and preventing the loss of intraepidermal nerve fibers and Merkel cells in the plantar skin. Concurrently, SAR7334 ameliorated anxiety-like behaviors in CIPN mice[8].

References:
[1] Ilatovskaya DV, Palygin O, Levchenko V, et al. The Role of Angiotensin II in Glomerular Volume Dynamics and Podocyte Calcium Handling. Sci Rep. 2017 Mar 22;7(1):299.
[2] Fang X, Dong S, Wu Y, et al. Ameliorated biomechanical properties of carotid arteries by puerarin in spontaneously hypertensive rats. BMC Complement Med Ther. 2021 Jun 22;21(1):173.
[3] Ducrocq GP, Anselmi L, Stella SL Jr, et al. Inhibition and potentiation of the exercise pressor reflex by pharmacological modulation of TRPC6 in male rats. J Physiol. 2025 Sep;603(18):5027-5052.
[4] Obara K, Takahashi S, Otake M, et al. Pharmacological Characteristics of Extracellular Ca2+ Influx Pathways Responsible for Platelet-Activating Factor-Induced Contractions in Rat Esophagus Smooth Muscle: Involvement of L-Type, Receptor-Operated, and Store-Operated Ca2+ Channels. Biol Pharm Bull. 2025;48(6):932-940.
[5] Uryash A, Flores V, Adams JA, et al. Memory and Learning Deficits Are Associated With Ca2+ Dyshomeostasis in Normal Aging. Front Aging Neurosci. 2020 Jul 16;12:224.
[6] Feng Y, Li M, Wang Y, et al. Activation of TRPC6 by AngⅡ Induces Podocyte Injury and Participates in Proteinuria of Nephrotic Syndrome. Front Pharmacol. 2022 Aug 3;13:915153.
[7] Maier T, Follmann M, Hessler G, et al. Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol-sensitive TRPC cation channels. Br J Pharmacol. 2015 Jul;172(14):3650-60.
[8] Jiang YY, Li X, Hu FX, et al. Electroacupuncture alleviates chemotherapy-induced peripheral neuropathy and anxiety by reducing TRPC6/PKC-dependent activation of glutamatergic neurons in the paraventricular thalamic nucleus. Neuroscience. 2026 Jan 9;592:97-110.

Protocol of SAR7334

Cell experiment [1]:

Cell lines

Immortalized mouse MPC5 podocytes

Preparation Method

MPC5 podocytes were cultured and matured in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37°C with 5% CO₂. Cells pretreated with SAR7334 (1μM) for 30 minutes, followed by stimulation with Angiotensin II (AngII; 1μM) for 24 hours.

Reaction Conditions

1μM; 30min pretreatment.

Applications

SAR7334 significantly inhibited the AngII-induced overexpression of TRPC6, AT1R, and Caspase-3 proteins. SAR7334 also attenuated the degradation of podocyte structural proteins Nephrin and Podocin. SAR7334 inhibited the fluorescence intensity of intracellular calcium (Ca²⁺) and reduced cell apoptosis.

Animal experiment [2]:

Animal models

Male C57BL/6J mice with cisplatin-induced chemotherapy-induced peripheral neuropathy (CIPN)

Preparation Method

A CIPN mouse model was established by administering cisplatin. SAR7334 (10mg/kg) was intraperitoneally injected beginning one day before the second cycle of cisplatin administration and continued for 7 days.

Dosage form

10mg/kg; i.p.; once daily for 7 days.

Applications

SAR7334 alleviated cisplatin-induced CIPN, indicated by an increased paw withdrawal threshold and a shortened response time to an adhesive stimulus. SAR7334 also blocked the loss of intra-epidermal nerve fibers (IENFs) and Merkel cells in the plantar skin. Furthermore, SAR7334 improved anxiety-like behaviors in CIPN mice, increasing activity in the central area of the open field and in the open arms of the elevated plus maze. SAR7334 inhibited the activation of TRPC6 and PKC, and downregulated the excitability markers p-CAMKII and c-Fos in the paraventricular thalamic nucleus (PVT).

References:
[1] Feng Y, Li M, Wang Y, et al. Activation of TRPC6 by AngⅡ Induces Podocyte Injury and Participates in Proteinuria of Nephrotic Syndrome. Front Pharmacol. 2022 Aug 3;13:915153.
[2] Jiang YY, Li X, Hu FX, et al. Electroacupuncture alleviates chemotherapy-induced peripheral neuropathy and anxiety by reducing TRPC6/PKC-dependent activation of glutamatergic neurons in the paraventricular thalamic nucleus. Neuroscience. 2026 Jan 9;592:97-110.

Chemical Properties of SAR7334

Cas No. 1333210-07-3 SDF
Canonical SMILES N[C@@H](C1)CCCN1[C@@H]2CC3=CC=CC=C3[C@H]2OC4=C(Cl)C=C(C#N)C=C4
Formula C21H22ClN3O M.Wt 367.87
Solubility DMSO : ≥ 370 mg/mL (1005.79 mM) Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of SAR7334

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.7184 mL 13.5918 mL 27.1835 mL
5 mM 543.7 μL 2.7184 mL 5.4367 mL
10 mM 271.8 μL 1.3592 mL 2.7184 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of SAR7334

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % saline
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Reviews

Review for SAR7334

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%